These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 6247892

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Synthesis of thromboxane B2 in incubates of dog platelet-rich plasma with arachidonic acid and its inhibition by different drugs.
    Chignard M, Vargaftig BB, Sors H, Dray F.
    Biochem Biophys Res Commun; 1978 Dec 29; 85(4):1631-9. PubMed ID: 743319
    [No Abstract] [Full Text] [Related]

  • 43. Prostaglandins and hemostasis: an overview.
    Stuart MJ.
    Adv Pediatr; 1983 Dec 29; 30():321-64. PubMed ID: 6231843
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
    Humphrey PP, Hallet P, Hornby EJ, Wallis CJ, Collington EW, Lumley P.
    Circulation; 1990 Jan 29; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817
    [Abstract] [Full Text] [Related]

  • 46. [Effect of various stimulators on cyclooxygenase activity, platelet aggregation and TxB2 synthesis after using a platelet inhibitor (Aspro Clear) in vivo and in vitro].
    Gorczynska E, James M, Wegrzynowicz R, Masiak M.
    Wiad Lek; 1985 Jul 01; 38(13):920-5. PubMed ID: 3933184
    [No Abstract] [Full Text] [Related]

  • 47. The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro.
    Best LC, Holland TK, Jones PB, Russell RG.
    Thromb Haemost; 1980 Feb 29; 43(1):38-40. PubMed ID: 6773171
    [Abstract] [Full Text] [Related]

  • 48. Platelet rich plasma transforms exogenous prostaglandin endoperoxide H2 into thromboxane A2.
    Fitzpatrick FA, Gorman RR.
    Prostaglandins; 1977 Nov 29; 14(5):881-9. PubMed ID: 594390
    [Abstract] [Full Text] [Related]

  • 49. Independence of the cyclic AMP-lowering activity of thromboxane A2 from the platelet release reaction.
    Gorman RR, Wierenga W, Miller OV.
    Biochim Biophys Acta; 1979 Jan 29; 572(1):95-104. PubMed ID: 216409
    [No Abstract] [Full Text] [Related]

  • 50. Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy?
    Gresele P, Van Houtte E, Arnout J, Deckmyn H, Vermylen J.
    Thromb Haemost; 1984 Dec 29; 52(3):364. PubMed ID: 6099616
    [No Abstract] [Full Text] [Related]

  • 51. Aza-substituted omega-side-chain modifications of 7-oxabicyclo[2.2.1]heptane thromboxane A2 receptor antagonists: structure-activity relationships.
    Nakane M, Reid JA, Haslanger MF, Garber DP, Harris DN, Ogletree ML, Greenberg R.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Dec 29; 15():291-3. PubMed ID: 3004140
    [No Abstract] [Full Text] [Related]

  • 52. Inhibition of platelet thromboxane synthetase by 1-(3-benzyloxy-1[E]octenyl)imidazole.
    Sincholle D, Coquelet C, Bonne C.
    Arzneimittelforschung; 1986 Dec 29; 36(1):117-9. PubMed ID: 3082339
    [Abstract] [Full Text] [Related]

  • 53. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
    Bertelé V, Falanga A, Tomasiak M, Cerletti C, de Gaetano G.
    Thromb Haemost; 1984 Feb 28; 51(1):125-8. PubMed ID: 6326343
    [Abstract] [Full Text] [Related]

  • 54. An overview of antiplatelet and antithrombotic drugs.
    Verstraete M, Dejana E, Fuster V, Lapetina E, Moncada S, Mustard JF, Tans G, Vargaftig BB.
    Haemostasis; 1985 Feb 28; 15(2):89-99. PubMed ID: 3159632
    [No Abstract] [Full Text] [Related]

  • 55. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence.
    Miller OV, Ayer DE, Gorman RR.
    Biochim Biophys Acta; 1982 Jun 11; 711(3):445-51. PubMed ID: 6285985
    [Abstract] [Full Text] [Related]

  • 56. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
    Lancet; 1982 Nov 20; 2(8308):1156-7. PubMed ID: 6128469
    [No Abstract] [Full Text] [Related]

  • 57. Stereocontrolled synthesis of 7-oxabicyclo (2.2.1) heptane prostaglandin analogs as thromboxane A2 antagonists.
    Sprague PW, Heikes JE, Harris DN, Greenberg R.
    Adv Prostaglandin Thromboxane Res; 1980 Nov 20; 6():493-6. PubMed ID: 7189952
    [No Abstract] [Full Text] [Related]

  • 58. [Effect of isosorbide dinitrate on platelet aggregation and production of thromboxane B2].
    De Caterina R, Crea F, Giannessi D, Bernini W, Gazzetti P, Chierchia S, Distante A, L'Abbate A.
    Cardiologia; 1982 Nov 20; 27(3):315-7. PubMed ID: 6927441
    [No Abstract] [Full Text] [Related]

  • 59. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach.
    Needleman P, Whitaker MO, Wyche A, Watters K, Sprecher H, Raz A.
    Prostaglandins; 1980 Jan 20; 19(1):165-81. PubMed ID: 6247744
    [Abstract] [Full Text] [Related]

  • 60. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
    Bertelé V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, de Gaetano G.
    Blood; 1984 Jun 20; 63(6):1460-6. PubMed ID: 6426554
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.